In this issue:
TERIS: Teriflunomide & time to clinical MS in RIS
Genetic variants associated with MS progression
NOVA: clinical efficacy & patient-reported outcomes
Cognitive impairment, fatigue & depression in non-benign MS
Prior DMTs & ocrelizumab efficacy
Smouldering MS lesions & disease progression
Disability accrual in PPMS vs. SPMS
Ocrelizumab & loss of brain volume in relapsing MS
MOG & AQP4 antibodies among POMS patients
MS patient attitudes towards brain donation
Please login below to download this issue (PDF)